Personalized medicine: Does the molecular suit fit?

Oncologist

Volumn 18, Issue 6, 2013, Pages 653-654

  Liu, Edison T ^a   Johnston, Patrick G ^b  

^a JACKSON LABORATORY   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BIM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB;

CANCER GENETICS; CELL DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; DRUG COST; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; NONHUMAN; NOTE; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHARMACOGENETICS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84879478973     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0191     Document Type: Note

References (12)

1. Druker BJ. Perspectives on the development of imatinibandthefutureofcancerresearch. Nat Med 2009;15:1149-1152.
2. Slamon D, Eiermann W, Robert Net al. Adjuvant trastuzumab in HER2-positive breastcancer. N Engl J Med 2011;365:1273-1283.
3. Lilèvre A, Bachet JB, Le Corre Det al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66: 3992-3995.
4. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
5. Yang SH, Mechanic LE, Yang Pet al. Mutations in thetyrosinekinasedomainoftheepidermalgrowth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005;11:2106-2110.
6. Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviors oflungcancerbetween East Asiansand Caucasians. Chin J Cancer 2011;30:287-292.
7. Shankaran V, Obel J, Benson AB 3rd. Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. The Oncologist 2010;15:157-167.
8. Ng KP, Hillmer AM, Chuah CTet al. Acommon BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012;18:521-528.
9. Sullivan R, Peppercorn J, Sikora K et al. Deliver ing affordable cancer care in high-income countries. Lancet Oncol 2011;12:933-980.
10. Proposal fora Regulation ofthe European Parliament and of The Council on clinical trials on medicinal products forhuman use. Available at http:// ec.europa.eu/health/human-use/clinical-trials/ index_en.htm#rlctd. Accessed May9,2013.
11. European Commission. Protection ofpersonal data. Available at ec. europa. eu/justice/data-pro-tection. Accessed May9, 2013.
12. Biobanks for Europe: A challenge for governance. A report from the Expert Group on Dealing with Ethical and Regulatory Challenges of International Biobank Research. European Commission 2012. Available at http://www.coe.int/t/dg3/ healthbioethic/Activities/10_Biobanks/biobanks_ for_Europe.pdf. Accessed May9,2013.